<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118542</article-id><article-id pub-id-type="publisher-id">ACM-44767</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_75529909.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  异位妊娠药物治疗的研究进展
  Research Progress of Drug Therapy for Ectopic Pregnancy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>牛</surname><given-names>尧</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>娟</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晓勇</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>渠源</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>吉林大学第二医院，吉林 长春</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3697</fpage><lpage>3702</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  异位妊娠是指发生在宫外的妊娠，又被称为宫外孕。是妇科常见的疾病，发病频率较高，同时存在较高的死亡风险。近年来，随着此病早期诊断率大大提高，药物保守治疗成为更多患者的选择，但传统药物保守治疗即肌注甲氨蝶呤杀胚缺点较多。所以探求一种毒性小、治疗周期短，普适的药物保守治疗异位妊娠的方法，成为国内外学者关注的热点。本文着重对三种异位妊娠药物保守治疗的新方法加以概述，即靶向集落刺激因子-1受体信号、来曲唑(芳香化酶抑制剂)、无水乙醇绒毛靶向治疗异位妊娠。
   Ectopic pregnancy refers to pregnancy that occurs outside the uterus. It is a common gynecological disease with high incidence and high risk of death. In recent years, as the early diagnosis rate of the disease has been greatly improved, drug conservative treatment has become the choice for more patients, but there are many disadvantages of traditional drug conservative treatment, i.e. intramuscular methotrexate embryo killing. Therefore, to explore a less toxic, short treatment cycle and universal drug conservative treatment of ectopic pregnancy has become the focus of scholars at home and abroad. This article focuses on an overview of three new methods for conservative treatment of ectopic pregnancy with drugs, namely, targeted colony stimulating factor-1 receptor signal, letrozole (aromatase inhibitor), and absolute ethanol villi targeted therapy for ectopic pregnancy.
 
</p></abstract><kwd-group><kwd>异位妊娠，甲氨蝶呤，来曲唑，集落刺激因子-1，无水乙醇, Ectopic Pregnancies</kwd><kwd> Methotrexate</kwd><kwd> Etrozole</kwd><kwd> Colony Stimulating Factor-1</kwd><kwd> Anhydrous Ethanol</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>异位妊娠是指发生在宫外的妊娠，又被称为宫外孕。是妇科常见的疾病，发病频率较高，同时存在较高的死亡风险。近年来，随着此病早期诊断率大大提高，药物保守治疗成为更多患者的选择，但传统药物保守治疗即肌注甲氨蝶呤杀胚缺点较多。所以探求一种毒性小、治疗周期短，普适的药物保守治疗异位妊娠的方法，成为国内外学者关注的热点。本文着重对三种异位妊娠药物保守治疗的新方法加以概述，即靶向集落刺激因子-1受体信号、来曲唑(芳香化酶抑制剂)、无水乙醇绒毛靶向治疗异位妊娠。</p></sec><sec id="s2"><title>关键词</title><p>异位妊娠，甲氨蝶呤，来曲唑，集落刺激因子-1，无水乙醇</p></sec><sec id="s3"><title>Research Progress of Drug Therapy for Ectopic Pregnancy<sup> </sup></title><p>Yao Niu, Juan Feng, Fei Song, Xiaoyong Li, Quyuan Wang</p><p>The Second Hospital of Jilin University, Changchun Jilin</p><p><img src="//html.hanspub.org/file/59-1572499x4_hanspub.png?20210826083654818" /></p><p>Received: Jul. 23<sup>rd</sup>, 2021; accepted: Aug. 15<sup>th</sup>, 2021; published: Aug. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/59-1572499x5_hanspub.png?20210826083654818" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Ectopic pregnancy refers to pregnancy that occurs outside the uterus. It is a common gynecological disease with high incidence and high risk of death. In recent years, as the early diagnosis rate of the disease has been greatly improved, drug conservative treatment has become the choice for more patients, but there are many disadvantages of traditional drug conservative treatment, i.e. intramuscular methotrexate embryo killing. Therefore, to explore a less toxic, short treatment cycle and universal drug conservative treatment of ectopic pregnancy has become the focus of scholars at home and abroad. This article focuses on an overview of three new methods for conservative treatment of ectopic pregnancy with drugs, namely, targeted colony stimulating factor-1 receptor signal, letrozole (aromatase inhibitor), and absolute ethanol villi targeted therapy for ectopic pregnancy.</p><p>Keywords:Ectopic Pregnancies, Methotrexate, Etrozole, Colony Stimulating Factor-1, Anhydrous Ethanol</p><disp-formula id="hanspub.44767-formula39"><graphic xlink:href="//html.hanspub.org/file/59-1572499x6_hanspub.png?20210826083654818"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/59-1572499x7_hanspub.png?20210826083654818" /> <img src="//html.hanspub.org/file/59-1572499x8_hanspub.png?20210826083654818" /></p></sec><sec id="s5"><title>1. 引言</title><p>异位妊娠(Ectopic Pregnancies，简称EP)是指发生在子宫外的妊娠，又被称为宫外孕。输卵管是异位妊娠最常见的种植部位，约占异位种植的90%以上。其余种植部位也可见于腹腔、宫颈、卵巢、和剖宫产瘢痕处 [<xref ref-type="bibr" rid="hanspub.44767-ref1">1</xref>]。异位妊娠属于急腹症，是妇科常见的疾病，发病频率较高，根据2014年Cecchino, G. N.等人的统计，平均每1000例妊娠中约有11例异位妊娠 [<xref ref-type="bibr" rid="hanspub.44767-ref2">2</xref>]，并且死亡率高，约占怀孕前三个月所有与妊娠相关死亡的6%~13% [<xref ref-type="bibr" rid="hanspub.44767-ref3">3</xref>]。因此，此病一直备受妇产科医生的关注。</p></sec><sec id="s6"><title>2. 异位妊娠的发病机制</title><p>现如今异位妊娠的发病机制尚不清晰，但各种原因导致的输卵管受损、运输功能下降、输卵管狭窄、吸烟及体外受精都是异位妊娠的高危因素 [<xref ref-type="bibr" rid="hanspub.44767-ref4">4</xref>]。异位妊娠诊断依据靠超声检查及血中人绒毛膜促性腺激素含量来诊断。异位妊娠常用的治疗方法包括手术治疗、药物治疗和期待治疗。近年来，由于人绒毛膜促性腺激素(HCG)的灵敏定量测定和高分辨率经阴道的超声技术的飞速发展，异位妊娠的早期诊断率大大提高，使得应用药物保守治疗异位妊娠的成功率大大增加 [<xref ref-type="bibr" rid="hanspub.44767-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44767-ref6">6</xref>]。</p></sec><sec id="s7"><title>3. 传统异位妊娠药物保守治疗方法</title><sec id="s7_1"><title>3.1. 肌肉注射甲氨蝶呤(MTX)治疗异位妊娠</title><p>甲氨蝶呤是一种针对滋养细胞DNA合成的化疗药物，通过抑制患者体内的二氢叶酸还原酶，从而干扰滋养细胞分裂，达到使胚胎停止发育的目的 [<xref ref-type="bibr" rid="hanspub.44767-ref7">7</xref>]。临床应用较为广泛，但同样存在着很多弊端，现有的临床数据证实甲氨蝶呤保守治疗异位妊娠大概需要24~48天，失败率大约在25%~30%，且副作用大 [<xref ref-type="bibr" rid="hanspub.44767-ref8">8</xref>]。它不仅具有潜在威胁生命的肾毒性、肝毒性、肺损伤和骨髓抑制等化学治疗药物共有的副作用，而且2018年易玲等 [<xref ref-type="bibr" rid="hanspub.44767-ref9">9</xref>] 研究发现甲氨蝶呤治疗会部分影响卵巢储备和未来的生育潜力。同时高β-人绒毛膜促性腺激素(β-hCG)或胎儿心跳(FHB)阳性的患者是甲氨蝶呤治疗的禁忌症 [<xref ref-type="bibr" rid="hanspub.44767-ref10">10</xref>]。</p></sec><sec id="s7_2"><title>3.2. 5-氟尿嘧啶(5-FU)治疗异位妊娠</title><p>5-氟尿嘧啶(5-FU)是介入治疗中常用的抗代谢药物，可通过抑制胸苷酸合成酶的活性诱导胚泡凋亡，从而干扰DNA或RNA的合成，抑制细胞周期和存活 [<xref ref-type="bibr" rid="hanspub.44767-ref11">11</xref>]。2013年白峰 [<xref ref-type="bibr" rid="hanspub.44767-ref12">12</xref>] 等在研究中称，5-氟尿嘧啶治疗异位妊娠的成功率约为84.2%。但5-氟尿嘧啶为化疗药物，副作用随着计量的增长而增大。现临床已慎用。</p></sec><sec id="s7_3"><title>3.3. 中药治疗异位妊娠</title><p>中药治疗异位妊娠主要利用其杀胚及活血化瘀功能，调动巨噬细胞吞噬作用杀死胚胎，同时改善血液循环，提高腹膜通透性，促进胶原酶及纤溶酶活性，使得血肿与妊娠产物更快的被吸收。可以使用单味中药，也可多味中药联合使用。其中比较常用的单味中药有：天花粉、蜈蚣、紫草等。多味中药联合使用如：宫外孕I号(丹参、赤芍、桃仁)、宫外孕II号(丹参、赤芍、桃仁、三棱、莪术) [<xref ref-type="bibr" rid="hanspub.44767-ref13">13</xref>]。经过大量临床研究中药治疗异位妊娠的成功率也很高。2018年周婷等 [<xref ref-type="bibr" rid="hanspub.44767-ref14">14</xref>] 运用天花粉治疗异位妊娠成功率高达95.35%。但是我们在中药治疗的作用机理的研究尚不足。而且根据大量文献报道，中药易引起患者产生过敏，临床上较少使用。</p><p>所以，探求一种，经济、高效。相对普适且毒副作用小的新型药物保守治疗方法，成为近几年研究的热点。本文将列举三种目前对于本病药物保守治疗研究的新方法。</p></sec></sec><sec id="s8"><title>4. 异位妊娠药物治的新方法</title><sec id="s8_1"><title>4.1. 靶向集落刺激因子-1受体信号治疗异位妊娠</title><p>集落刺激因子-1 (CSF-1)是一种糖蛋白，它可以调节巨噬细胞增值分化，支持绒毛外滋养细胞的生长和增殖，促进胚胎植入子宫和胎盘生长 [<xref ref-type="bibr" rid="hanspub.44767-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.44767-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.44767-ref17">17</xref>]。早在1989年便证实集落刺激因子-1 (CSF-1)和集落刺激因子-1受体(CSF-1R)在正常宫内妊娠的胎盘组织中高表达 [<xref ref-type="bibr" rid="hanspub.44767-ref18">18</xref>]。2020年S. Furquan Ahmad等人 [<xref ref-type="bibr" rid="hanspub.44767-ref19">19</xref>] 通过免疫组织化学定位的方法证实CSF-1信号系统也存在于女性输卵管异位着床部位的滋养层细胞中。同时其团队发现一种集落刺激因子-1受体(CSF-1R)的拮抗剂：GW2580。GW2580的功能为选择性抑制CSF-1R的酪氨酸激酶结构域，证明其可以起到使巨噬细胞浸润减少，抑制细胞增殖的作用，可以消除CSF-1诱导的滋养层细胞的增殖和迁移。进而从药理学角度认为对CSF-1/CSF-1R信号轴的干扰可能是新的治疗方法的基础。为我们提供了一个治疗异位妊娠的新思路。相比甲氨蝶呤这种广泛化疗药物，这种靶向治疗的方法无疑是毒性更小、更有效、更容易获得的针对异位妊娠的治疗。</p></sec><sec id="s8_2"><title>4.2. 来曲唑(芳香化酶抑制剂)治疗异位妊娠</title><p>来曲唑是第三代芳香化酶抑制剂，能通过可逆或不可逆地抑制芳香化酶来阻止雄烯二酮转化为雌二醇。几十年的临床证实其具有安全性高，耐受性好，成本低廉及不良反应小的优点，在临床上已广泛应用于抑制乳腺癌妇女雌激素的产生 [<xref ref-type="bibr" rid="hanspub.44767-ref20">20</xref>]。同时，来曲唑这类芳香化酶抑制剂也已被证明可以成功抑制育龄期妇女雌激素的产生 [<xref ref-type="bibr" rid="hanspub.44767-ref21">21</xref>]。2020年Mohamed F. Mitwally等人 [<xref ref-type="bibr" rid="hanspub.44767-ref22">22</xref>] 认为如果抑制雌激素合成酶(芳香化酶)，孕酮就不会在维持早孕(包括异位妊娠)方面发挥生理作用。进而研究芳香化酶抑制剂—来曲唑治疗异位妊娠的疗效，并与甲氨蝶呤进行了比较。主要结果是通过血HCG水平低于实验室免疫检测而确定异位妊娠完全消失。同时也将卵巢储备生化参数、抗苗勒管激素(AMH)水平、血红蛋白水平、血小板计数及天冬氨酸氨基转移酶(AST)和丙氨酸氨基转移酶(ALT)的指标作为次要对比结果。最终得出结论与甲氨蝶呤组相比，来曲唑组血HCG水平下降的更快，但差异没有统计学意义；同时相比于来曲唑组，甲氨蝶呤组的AMH水平较低，血红蛋白水平在7天后显著下降，并且存在ALT、AST水平升高，血小板计数下降的情况。但是结果仍然没有统计学意义。Mohamed F. Mitwally等人也在文章中提到，实验存在样本量小和研究非随机设计等局限性，但是通过结果证明，来曲唑在处理早期异位妊娠方面可能是一种更安全的方法，来曲唑有望成为一种有前途治疗异位妊娠的药物。</p></sec><sec id="s8_3"><title>4.3. 无水乙醇(AE)绒毛靶向治疗异位妊娠</title><p>前文已述，使用甲氨蝶呤杀胚治疗异位妊娠有一定的局限性，即不适用于高β-人绒毛膜促性腺激素(β-hCG)或胎儿心跳(FHb)阳性的患者。那么面对这种情况的患者又如何保守治疗呢？从2006年开始Hisao Osada等人 [<xref ref-type="bibr" rid="hanspub.44767-ref23">23</xref>] 便开始研究经阴道超声引导孕囊中注射无水乙醇治疗输卵管妊娠，他们将2002年至2004年门诊接受体外受精后被诊断为输卵管妊娠的平均年龄为39岁的69名患者作为研究对象。在不使用任何麻醉剂的情况下由阴道超声引导用23号针将0.3 ml无水乙醇注射到孕囊及其周围区域，观察注射前后血清β-hCG水平，评价疗效。结果显示在69例患者中，60例治疗有效的患者在注射后2小时内血清β-hCG水平均下降了10%~30%。他们中的56例在注射后20天内血HCG水平降至20 ml U/mL或以下。从而得出孕囊注射无水乙醇相对于甲氨蝶呤治疗异位妊娠的优点在于1) 注射后2小时即可进行疗效评估；2)无水乙醇用量少，对机体影响小；3) 因为此方法为局部注射，故在治疗异位妊娠的情况下不会影响宫内胎儿；4) 无水乙醇的防腐性能意味着治疗过程中局部感染的风险降低，同时有利于经阴道操作；5) 因无水乙醇不含水，注射后在超声上显示注射部位为高强度图像，便于再次注射 [<xref ref-type="bibr" rid="hanspub.44767-ref23">23</xref>]。2018年Hisao Osada等人 [<xref ref-type="bibr" rid="hanspub.44767-ref24">24</xref>] 开发出一种新方法，命名为“滋养细胞靶向疗法”，即使用超声引导下经阴道将无水乙醇注射到占据绒毛膜反应在妊娠囊周围形成的高回声环 [<xref ref-type="bibr" rid="hanspub.44767-ref25">25</xref>] 而非妊娠囊，并通过回顾性临床研究证实此种方法对宫颈妊娠及剖宫产瘢痕妊娠的治疗同样有效 [<xref ref-type="bibr" rid="hanspub.44767-ref24">24</xref>]。2020年Hisao Osada等 [<xref ref-type="bibr" rid="hanspub.44767-ref26">26</xref>] 再次将这种治疗方法更名为“无水乙醇绒毛靶向治疗异位妊娠”。他认为无水乙醇针对的是合体滋养细胞，即绒毛的外层，由于绒毛周围存在腔隙，注射无水乙醇可以直接影响合体滋养细胞。他们对242例患者进行研究，最终治疗成功率为91.7% (222例)，其中输卵管妊娠治疗成功率为92.5%，输卵管间质部妊娠治疗成功率为88.2%，剖宫产瘢痕妊娠、宫颈妊娠、胎儿心跳阳性患者治疗成功率为100%。但是在治疗过程中也发现注射无水乙醇的一种副反应，即当无水乙醇渗漏到腹腔时会长生腹膜刺激症状，可以应用止痛药，通常在1~3小时后症状会消失 [<xref ref-type="bibr" rid="hanspub.44767-ref26">26</xref>]。无水乙醇绒毛靶向治疗副反应更小，特异性强不影响宫内妊娠，方便再次注射。此方法有可能取代传统手术干预及甲氨蝶呤治疗，成为一种新型的治疗异位妊娠的方法。</p></sec></sec><sec id="s9"><title>5. 结论和展望</title><p>随着“二孩”政策的开放及体外受精技术的发展，异位妊娠的发生率逐年升高，对于异位妊娠的治疗，一直是科学工作者及临床医生比较关注的问题。目前，AWMF (德国科学医学会协会)或DGGG (德国妇产科学会)没有关于治疗EP的适当方法的指南 [<xref ref-type="bibr" rid="hanspub.44767-ref27">27</xref>]。自从Tanaka等报告以来，甲氨蝶呤疗法被认为是治疗异位妊娠常用的方法已有近40年的历史 [<xref ref-type="bibr" rid="hanspub.44767-ref28">28</xref>]，同时也被证实是腹腔镜手术的替代疗法 [<xref ref-type="bibr" rid="hanspub.44767-ref29">29</xref>]。但甲氨蝶呤作为一种抗肿瘤的化学治疗药物，它副作用大、使用局限，以及治疗周期长的弊端也使临床医生对它又爱又恨。所以国内外对于异位妊娠药物治疗的研究从未停止，本综述阐述了三种治疗异位妊娠药物保守治疗的新方法，以及和传统药物甲氨蝶呤治疗相比的优势。但这三种方法仍存在一定的不足，如GW2580作为集落刺激因子-1受体(CSF-1R)的拮抗剂，仅仅从分子角度阐述了治疗异位妊娠的可能性，尚未进行临床研究；来曲唑(芳香化酶抑制剂)的临床研究仅仅提供了一种思路，因为样本量原因并不具有统计学意义；无水乙醇绒毛靶向治疗异位妊娠存在腹膜刺激症状的并发症等。综上所述，对于异位妊娠药物保守治疗的研究远没有结束，希望本综述能抛砖引玉为广大同仁提供一个思路或启发。我们共同期待未来出现一种毒性小，治疗成功率高的针对异位妊娠的药物保守治疗方法。</p></sec><sec id="s10"><title>文章引用</title><p>牛 尧,冯 娟,宋 飞,李晓勇,王渠源. 异位妊娠药物治疗的研究进展Research Progress of Drug Therapy for Ectopic Pregnancy[J]. 临床医学进展, 2021, 11(08): 3697-3702. https://doi.org/10.12677/ACM.2021.118542</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44767-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bouyer, J., Coste, J., Fernandez, H., Pouly, J.L. and Job-Spira, N. (2002) Sites of Ectopic Pregnancy: A 10 Year Population-Based Study of 1800 Cases. Human Reproduction, 17, 3224-3230. &lt;br&gt;https://doi.org/10.1093/humrep/17.12.3224</mixed-citation></ref><ref id="hanspub.44767-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Cecchino, G.N., Araujo Jr., E. and Elito Jr., J. (2014) Methotrexate for Ectopic Pregnancy: When and How. Archives of Gynecology &amp; Obstetrics, 290, 417-423. &lt;br&gt;https://doi.org/10.1007/s00404-014-3266-9</mixed-citation></ref><ref id="hanspub.44767-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Parker, V.L. and Srinivas, M. (2016) Non-Tubal Ectopic Pregnancy. Archives of Gynecology &amp; Obstetrics, 294, 19-27.  
&lt;br&gt;https://doi.org/10.1007/s00404-016-4069-y</mixed-citation></ref><ref id="hanspub.44767-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Nio-Kobayashi, J., Abidin, H.B.Z., Brown, J.K., Iwanaga, T., Horne, A.W. and Duncan, W.C. (2016) Cigarette Smoking Alters Sialylation in the Fallopian Tube of Women, with Implications for the Pathogenesis of Ectopic Pregnancy. Molecular Reproduction &amp; Development, 83, 1083-1091. &lt;br&gt;https://doi.org/10.1002/mrd.22747</mixed-citation></ref><ref id="hanspub.44767-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ankum, W.M., Van der Veen, F., Hamerlynck, J.V.T.H. and F.B. Lammes (1993) Pregnancy: Transvaginal Sonography and Human chorionic Gonadotrophin Measurements in Suspected Ectopic Pregnancy: A Detailed Analysis of a Diagnostic Approach. Human Reproduction, 8, 1307-1311. &lt;br&gt;https://doi.org/10.1093/oxfordjournals.humrep.a138247</mixed-citation></ref><ref id="hanspub.44767-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lipscomb, G.H., Givens, V.M., Meyer, N.L. and Bran, D. (2005) Comparison of Multidose and Single-Dose Methotrexate Protocols for the Treatment of Ectopic Pregnancy. Obstetrical and Gynecological Survey, 60, 646-647.  
&lt;br&gt;https://doi.org/10.1097/01.ogx.0000180851.01817.9f</mixed-citation></ref><ref id="hanspub.44767-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">刘浏. 米非司酮联合甲氨蝶呤保守治疗宫外孕的临床效果观察[J]. 中国医药指南, 2019, 17(22): 79-80.</mixed-citation></ref><ref id="hanspub.44767-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Guven, E.S.G., Dilbaz, S., Dilbaz, B., Aykan Yildirim, B., Akdag, D. and Haberal, A. (2010) Comparison of Single and Multiple Dose Methotrexate Therapy for Unruptured Tubal Ectopic Pregnancy: A Prospective Randomized Study. Acta Obstetricia Et Gynecologica Scandinavica, 89, 889-895. &lt;br&gt;https://doi.org/10.3109/00016349.2010.486825</mixed-citation></ref><ref id="hanspub.44767-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">易灵, 胡庆兰, 崔艳萍, 黄文静, 刘艳红. 甲氨蝶呤全身用药治疗输卵管妊娠不同给药次数对卵巢储备功能的影响[J]. 中国医学创新, 2018, 15(5): 98-101.</mixed-citation></ref><ref id="hanspub.44767-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rau, R. and Herborn, G. (2004) Benefit and Risk of Methotrexate Treatment in Rheumatoid Arthritis. Clinical &amp; Experimental Rheumatology, 22, S83-S94.</mixed-citation></ref><ref id="hanspub.44767-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Gao, J., Li, X., Chen, J., Gong, W., Yue, K. and Wu, Z. (2018) Uterine Artery Embolization Combined with Local Infusion of Methotrexate and 5-Fluorouracil in Treating Ectopic Pregnancy: A CONSORT-Compliant Article. Medicine, 97, Article No. e9722. &lt;br&gt;https://doi.org/10.1097/MD.0000000000009722</mixed-citation></ref><ref id="hanspub.44767-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">白锋. 氟尿嘧啶治疗异位妊娠疗效观察[J]. 中国社区医师: 综合版, 2013, 15(4): 80-81.</mixed-citation></ref><ref id="hanspub.44767-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">孙冬莉, 邓高丕. 中西医治疗异位妊娠作用机理的研究进展[J]. 中国中医药现代远程教育, 2018, 16(12): 155-158.</mixed-citation></ref><ref id="hanspub.44767-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">周婷. 天花粉治疗异位妊娠患者的临床效果[J]. 医疗装备, 2018, 31(9): 107-108.</mixed-citation></ref><ref id="hanspub.44767-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Y., Qin, J., Lan, L., Li, N., Wang, C., He, P., et al. (2014) M-CSF Cooperating with NFκB Induces Macrophage Transformation from M1 to M2 by Upregulating c-Jun. Cancer Biology &amp; Therapy, 15, 99-107.  
&lt;br&gt;https://doi.org/10.4161/cbt.26718</mixed-citation></ref><ref id="hanspub.44767-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hamilton, G., Lysiak, J.J., Watson, A.J. and Lala, P.K. (1998) Effects of Colony Stimulating Factor-1 on Human Extravillous Trophoblast Growth and Invasion. Journal of Endocrinology, 159, 69-77.  
&lt;br&gt;https://doi.org/10.1677/joe.0.1590069</mixed-citation></ref><ref id="hanspub.44767-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Rahmati, M., Petitbarat, M., Dubanchet, S., Bensussan, A., Chaouat, G. and Ledee, N. (2015) Colony Stimulating Factors 1, 2, 3 and Early Pregnancy Steps: From Bench to Bedside. Journal of Reproductive Immunology, 109, 1-6.  
&lt;br&gt;https://doi.org/10.1016/j.jri.2015.01.005</mixed-citation></ref><ref id="hanspub.44767-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Arceci, R.J., Shanahan, F. and Pollard, S.J.W. (1989) Temporal Expression and Location of Colony-Stimulating Factor 1 (CSF-1) and Its Receptor in the Female Reproductive Tract are Consistent with CSF-1-Regulated Placental Development. Proceedings of the National Academy of Sciences of the United States of America, 86, 8818-8822.  
&lt;br&gt;https://doi.org/10.1073/pnas.86.22.8818</mixed-citation></ref><ref id="hanspub.44767-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ahmad, S.F., Duncan, W.C., Campbell, L.L., Beaty, R.E., Koscielniak, M., Collins, F., et al. (2020) Targeting Colony Stimulating Factor-1 Receptor Signalling to Treat Ectopic Pregnancy. Scientific Reports, 10, Article No. 15638. 
&lt;br&gt;https://doi.org/10.1038/s41598-020-72785-y</mixed-citation></ref><ref id="hanspub.44767-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Lin, N.U. and Winer, E.P. (2008) Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. Journal of Clinical Oncology, 26, 798-805. &lt;br&gt;https://doi.org/10.1200/JCO.2007.15.0946</mixed-citation></ref><ref id="hanspub.44767-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Mitwally, M.F.M. and Casper, R.F. (2019) Reprint of: Use of an Aromatase Inhibitor for Induction of Ovulation in Patients with an Inadequate Response to Clomiphene Citrate. Fertility and Sterility, 112, e178-e182.  
&lt;br&gt;https://doi.org/10.1016/j.fertnstert.2019.08.087</mixed-citation></ref><ref id="hanspub.44767-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Mitwally, M.F., Hozayen, W.G., Hassanin, K.M.A., Abdalla, K.A. and Abdalla, N.K., (2020) Aromatase Inhibitor Letrozole: A Novel Treatment for Ectopic Pregnancy. Fertility and Sterility, 114, 361-366.  
&lt;br&gt;https://doi.org/10.1016/j.fertnstert.2020.04.001</mixed-citation></ref><ref id="hanspub.44767-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kaijima, H., Osada, H., Kato, K., Segawa, T., Takehara, Y., Teramoto, S., et al. (2006) The Efficacy and Safety of Managing Ectopic Pregnancies with Transvaginal Ultrasound-Guided Local Injections of Absolute Ethanol. Journal of Assisted Reproduction &amp; Genetics, 23, 293-298. &lt;br&gt;https://doi.org/10.1007/s10815-006-9037-1</mixed-citation></ref><ref id="hanspub.44767-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Osada, H., Teramoto, S., Kaijima, H., Segawa, T., Miyauchi, O., Nagaishi, M., et al. (2018) A Novel Treatment for Cervical and Cesarean Section Scar Pregnancies by Transvaginal Injection of Absolute Ethanol to Trophoblasts: Efficacy in 19 Cases. Journal of Minimally Invasive Gynecology, 26, 129-134. &lt;br&gt;https://doi.org/10.1016/j.jmig.2018.04.021</mixed-citation></ref><ref id="hanspub.44767-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Doubilet, P.M. (2014) Ultrasound Evaluation of the First Trimester. Radiologic Clinics of North America, 52, 1191-1199.</mixed-citation></ref><ref id="hanspub.44767-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Osada, H., Teramoto, S., Kaijima, H., Segawa, T., Nagaishi, M., Shozu, M., et al. (2020) Managing Ectopic Pregnancies by Targeting Chorionic Villi with a Transvaginal Injection of Ethanol into the Lacunar Space. Biomedicines, 8, Article No. 202. &lt;br&gt;https://doi.org/10.3390/biomedicines8070202</mixed-citation></ref><ref id="hanspub.44767-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Eisner, S.M., Ebert, A.D. and David, M. (2020) Rare Ectopic Pregnancies—A Literature Review for the Period 2007-2019 on Locations Outside the Uterus and Fallopian Tubes. Geburtshilfe und Frauenhlkunde, 80, 686-701. 
&lt;br&gt;https://doi.org/10.1055/a-1181-8641</mixed-citation></ref><ref id="hanspub.44767-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Tanaka, T., Hayashi, H., Kutsuzawa, T., Fujimoto, S. and Ichinoe, K. (1982) Treatment of Interstitial Ectopic Pregnancy with Methotrexate: Report of a Successful Case. Fertility and Sterility, 37, 851-852.  
&lt;br&gt;https://doi.org/10.1016/S0015-0282(16)46349-1</mixed-citation></ref><ref id="hanspub.44767-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Hajenius, P.J., Engelsbel, S., Mol, B.W., Van der Veen, F., Ankum, W.M., Bossuyt, P.M., et al. (1997) Randomised Trial of Systemic Methotrexate versus Laparoscopic Salpingostomy in Tubal Pregnancy. Lancet, 350, 774-779.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(97)05487-1</mixed-citation></ref></ref-list></back></article>